HUYABIO International Receives Regulatory Approval for HBI-8000 Monotherapy of Adult T-Cell Leukemia/Lymphoma in Japan

HUYABIO International™ announced the regulatory approval for HBI-8000 monotherapy of relapsed or refractory adult T-cell leukemia/lymphoma (ATL) by the Japanese Pharmaceuticals and Medical Devices Agency. The drug was approved based on data from a Phase IIb study that involved 23 patients with aggressive ATL in Japan.